HR Execs on the Move

HVS International

www.hvs.com

 
HVS Executive Search provides human capital advisory services to leaders in the hotel, restaurant, food service and travel/leisure industries. Practice areas include senior-level executive search, mid-management recruitment and performance improvement. With offices in New York, London, New Delhi and Hong Kokng; HVS Executive Search has unparalleled access to the global hospitality industry. HVS Executive Search is a division of HVS, a fully integrated consulting firm focused on the hospitality industry. Founded in 1980, HVS is the world`s leading specialist in hospitality consulting. With over 30 offices globally, HVS offers unparalleled worldwide market expertise.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hvs.com
  • 372 Willis Ave
    Mineola, NY USA 11501-1818
  • Phone: 516.248.8828

Executives

Name Title Contact Details
Greg Palmer
Senior Vice President Profile
Whitney Harper
Director of Human Resources and Professional Development Profile
Whitney Harper
Director of Human Resources and Professional Development Profile

Similar Companies

Zircon Corporation

Zircon Corporation is a Campbell, CA-based company in the Business Services sector.

Jubilee Group Inc

Jubilee Group Inc is a Saint Clair Shores, MI-based company in the Business Services sector.

advertiseATLANTA.com

advertiseATLANTA.com is a Atlanta, GA-based company in the Business Services sector.

MINER and SILVERSTEIN

MINER & SILVERSTEIN is a New London, CT-based company in the Business Services sector.

Cellerant

Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.